Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx’s Myeloma Drug Kyprolis Fits ODAC’s View On Accelerated Approval

Executive Summary

FDA’s Oncologic Drugs Advisory Committee overwhelmingly endorsed the second-generation proteasome inhibitor for accelerated approval in the relapsed/refractory population. Onyx’s reliance on a single-arm study was appropriate given the lack of treatment options in a heavily pre-treated population, said ODAC members, who also looked favorably upon the company’s advanced plans for confirmatory trials.

Advertisement

Related Content

Puma Breaks A Long Losing Streak For Sponsors At ODAC
Novartis’ Panobinostat Review Panel Could Scrutinize Survival Data
Onyx’s Kyprolis Sails Through FDA Panel, Boosted By Confirmatory Trial Plans
Safety Concerns Weigh On Onyx’s Carfilzomib In Multiple Myeloma
Onyx Files Carfilzomib For Accelerated Approval With Two Phase III Trials Ongoing
Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
Adcetris Review Adds Some Clarity To Principles For Accelerated Approval
Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel